Stock listing
NASDAQ:HCWB HCW Biologics Inc. Stock
Home listing (NASDAQ) of HCW Biologics Inc.
Follow HCW Biologics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:HCWB
$0.749 USD -0.015 (-1.9%)
Close on Nov 20, 2026
- Day range
- $0.700 – $0.795 USDNov 20, 2026
- Volume
- 23,620 sharesNov 20, 2026
- Market cap
- $2.35M USDAt the close on Nov 20, 2026 · price × 3.14M shares outstanding
- 52-week range
- $0.700 – $23.940 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $760,531 USDMedian day 59,529 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:HCWB · Home | $0.749 USD | -0.015 (-1.9%) | 23,620 | $0.720 | $0.795 | $0.700 | $0.764 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HCWB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.749 | -0.015 | -1.9% | $0.720 | $0.795 | $0.700 | 23,620 | |
| $0.764 | -0.013 | -1.6% | $0.777 | $0.840 | $0.758 | 19,733 | |
| $0.777 | -0.023 | -2.9% | $0.810 | $0.817 | $0.777 | 15,175 | |
| $0.800 | +0.027 | +3.5% | $0.840 | $0.846 | $0.743 | 87,029 | |
| $0.773 | -0.027 | -3.4% | $0.807 | $0.857 | $0.773 | 22,272 | |
| $0.801 | -0.059 | -6.9% | $0.894 | $0.894 | $0.764 | 36,105 | |
| $0.860 | -0.080 | -8.5% | $0.950 | $0.996 | $0.860 | 35,538 | |
| $0.940 | -0.014 | -1.5% | $0.959 | $1.000 | $0.940 | 20,983 | |
| $0.954 | -0.066 | -6.5% | $1.010 | $1.055 | $0.950 | 42,849 | |
| $1.020 | -0.020 | -1.9% | $1.025 | $1.045 | $1.010 | 22,434 | |
| $1.040 | -0.040 | -3.7% | $1.110 | $1.110 | $1.010 | 88,075 | |
| $1.080 | -0.070 | -6.1% | $1.100 | $1.150 | $1.080 | 17,600 | |
| $1.150 | +0.030 | +2.7% | $1.180 | $1.180 | $1.090 | 37,764 | |
| $1.120 | +0.020 | +1.8% | $1.110 | $1.280 | $1.110 | 73,686 | |
| $1.100 | -0.080 | -6.8% | $1.160 | $1.189 | $1.100 | 34,188 | |
| $1.180 | -0.040 | -3.3% | $1.160 | $1.220 | $1.160 | 33,151 | |
| $1.220 | +0.080 | +7.0% | $1.160 | $1.240 | $1.160 | 59,529 | |
| $1.140 | +0.040 | +3.6% | $1.150 | $1.150 | $1.100 | 19,915 | |
| $1.100 | -0.070 | -6.0% | $1.180 | $1.180 | $1.100 | 30,444 | |
| $1.170 | +0.050 | +4.5% | $1.120 | $1.191 | $1.090 | 80,400 | |
| $1.120 | -0.040 | -3.4% | $1.150 | $1.150 | $1.100 | 45,600 | |
| $1.160 | -0.010 | -0.9% | $1.170 | $1.210 | $1.150 | 49,700 | |
| $1.170 | -0.060 | -4.9% | $1.250 | $1.270 | $1.170 | 97,900 | |
| $1.230 | -0.010 | -0.8% | $1.240 | $1.340 | $1.230 | 98,900 | |
| $1.240 | +0.010 | +0.8% | $1.230 | $1.270 | $1.220 | 77,700 | |
| $1.230 | +0.060 | +5.1% | $1.170 | $1.280 | $1.150 | 48,500 | |
| $1.170 | -0.090 | -7.1% | $1.241 | $1.260 | $1.140 | 57,500 | |
| $1.260 | -0.220 | -14.9% | $1.300 | $1.450 | $1.250 | 2,129,900 | |
| $1.480 | -0.120 | -7.5% | $1.560 | $1.600 | $1.470 | 43,000 | |
| $1.600 | +0.070 | +4.6% | $1.600 | $1.728 | $1.520 | 79,900 | |
| $1.530 | -0.030 | -1.9% | $1.590 | $1.610 | $1.510 | 46,400 | |
| $1.560 | -0.010 | -0.6% | $1.550 | $1.620 | $1.540 | 30,600 | |
| $1.570 | -0.070 | -4.3% | $1.610 | $1.630 | $1.550 | 37,700 | |
| $1.640 | -0.040 | -2.4% | $1.640 | $1.690 | $1.550 | 82,000 | |
| $1.680 | -0.010 | -0.6% | $1.660 | $1.721 | $1.650 | 64,600 | |
| $1.690 | -0.020 | -1.2% | $1.747 | $1.747 | $1.671 | 55,100 | |
| $1.710 | -0.040 | -2.3% | $1.770 | $1.823 | $1.710 | 48,200 | |
| $1.750 | -0.070 | -3.8% | $1.810 | $1.850 | $1.750 | 51,400 | |
| $1.820 | -0.110 | -5.7% | $1.860 | $1.895 | $1.710 | 102,200 | |
| $1.930 | -0.060 | -3.0% | $1.880 | $2.000 | $1.810 | 416,900 | |
| $1.990 | +0.330 | +19.9% | $1.690 | $3.120 | $1.670 | 13,666,200 | |
| $1.660 | -0.150 | -8.3% | $1.810 | $1.830 | $1.610 | 161,200 | |
| $1.810 | -0.100 | -5.2% | $1.910 | $1.980 | $1.700 | 132,900 | |
| $1.910 | +0.040 | +2.1% | $1.950 | $2.020 | $1.870 | 59,100 | |
| $1.870 | -0.080 | -4.1% | $2.000 | $2.150 | $1.870 | 87,500 | |
| $1.950 | -0.060 | -3.0% | $2.050 | $2.074 | $1.940 | 66,700 | |
| $2.010 | -0.040 | -2.0% | $2.090 | $2.100 | $1.890 | 86,500 | |
| $2.050 | -0.150 | -6.8% | $2.170 | $2.189 | $2.050 | 55,300 | |
| $2.200 | -0.040 | -1.8% | $2.240 | $2.325 | $2.180 | 97,800 | |
| $2.240 | -0.190 | -7.8% | $2.430 | $2.445 | $2.160 | 93,900 | |
| $2.430 | -0.030 | -1.2% | $2.420 | $2.520 | $2.410 | 29,200 | |
| $2.460 | -0.050 | -2.0% | $2.440 | $2.530 | $2.340 | 102,100 | |
| $2.510 | -0.430 | -14.6% | $2.520 | $2.720 | $2.100 | 3,078,600 | |
| $2.940 | +0.070 | +2.4% | $2.810 | $2.970 | $2.800 | 35,600 | |
| $2.870 | -0.485 | -14.5% | $3.340 | $3.340 | $2.700 | 127,100 | |
| $3.355 | -0.095 | -2.8% | $3.540 | $3.810 | $3.320 | 207,900 | |
| $3.450 | -0.140 | -3.9% | $3.510 | $3.730 | $3.300 | 543,900 | |
| $3.590 | +0.160 | +4.7% | $3.600 | $3.600 | $3.211 | 58,600 | |
| $3.430 | +0.260 | +8.2% | $3.200 | $3.430 | $3.000 | 120,200 | |
| $3.170 | +0.470 | +17.4% | $2.700 | $3.280 | $2.600 | 332,400 | |
| $2.700 | +0.100 | +3.8% | $2.690 | $2.700 | $2.550 | 60,600 | |
| $2.600 | +0.290 | +12.6% | $2.310 | $2.888 | $2.280 | 278,800 | |
| $2.310 | +0.130 | +6.0% | $2.320 | $2.323 | $2.150 | 307,700 | |
| $2.180 | +0.060 | +2.8% | $2.160 | $2.230 | $2.050 | 55,500 | |
| $2.120 | -0.180 | -7.8% | $2.260 | $2.380 | $2.060 | 90,100 |
Splits
2 splits since 2025 · NASDAQ:HCWB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation | |
| 1-for-40 | Consolidation |
- Ticker
- NASDAQ:HCWB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
Latest deck · March 2026
Investor Presentation (March 2026)
Investor deck · 20 slides
Latest news
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
Nov 16, 2026
Closed $0.80 (+3.5%) on Nov 16, 2026
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
Nov 6, 2026
Closed $1.02 (-1.9%) on Nov 6, 2026
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
Nov 6, 2026
Closed $1.02 (-1.9%) on Nov 6, 2026
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
Nov 5, 2026
Closed $1.04 (-3.7%) on Nov 5, 2026
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Oct 9, 2026
Closed $1.60 (+4.6%) on Oct 9, 2026
HCW Biologics Announces Pricing of $1.5 Million Private Placement
Sep 24, 2026
Closed $1.99 (+19.9%) on Sep 24, 2026
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Aug 17, 2026
Closed $2.52 (-6.0%) on Aug 17, 2026
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
Jul 29, 2026
Closed $2.58 (-0.2%) on Jul 29, 2026
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
Jul 23, 2026
Closed $2.88 (-13.9%) on Jul 23, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
Jun 30, 2026
Closed $4.99 (-5.1%) on Jun 30, 2026
HCW Biologics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 92 in all · newest Nov 16, 2026 · oldest 2021
- Decks
- 2 decks · latest March 2026
Where HCW Biologics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:HCWB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:HCWB | BOATS | United States | USD |
Valuation
EV/sales 1.2× against a median of 28.0×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $8.23M USD
- P/E
- Loss
- EV/sales
- 1.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- 96.6%
- Operating margin
- −103.9%
- Net margin
- −63.4%
- Debt to equity
- 1.0×
- Beta vs S&P 500
- 1.19
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Median of the others | US$2.39M | −US$907,868 | 0.7× | 28.0× | 0.3× | −540.4% | 0.0× | 1.41 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 48.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -28.32 · 1 analyst
- Revenue, year to Dec 2026
- 6.68M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Hing C. Wong | Chief Executive Officer |
| Rebecca Byam | Chief Financial Officer |
| Jack Egan | Vice President of Manufacturing and Development |
| Lee Flowers | Senior Vice President Business Development |
| Nicole Valdivieso | Vice President Legal Affairs |
| Peter Rhode | Chief Scientific Officer and Vice President Clinical Operations |
Board
| Director | Role |
|---|---|
| Hing C. Wong | Chief Executive Officer |
| Lisa M. Giles | Board Member |
| Rick S. Greene | |
| Scott T. Garrett | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | +3.5% |
| Q2 2026 | Aug 14, 2026 · After close | −6.0% |
| Q1 2026 | May 14, 2026 · After close | +262.0% |
| Q3 2025 | Nov 14, 2025 · After close | +2.0% |
| Q2 2025 | Aug 18, 2025 · After close | −11.4% |
| Q1 2025 | May 15, 2025 | +1.6% |
| Q4 2024 | Mar 28, 2025 · After close | −6.0% |
| Q3 2024 | Nov 14, 2024 · After close | −4.5% |
| Q2 2024 | Aug 14, 2024 · After close | −13.6% |
| Q1 2024 | Apr 1, 2024 · After close | +0.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 26, 2024 | +2.9% |
| Q3 2023 | Nov 14, 2023 · Before open | −17.7% |
| Q2 2023 | Aug 11, 2023 · Before open | +3.9% |
| Q1 2023 | May 9, 2023 · Before open | +4.9% |
| Q4 2022 | Mar 28, 2023 · After close | +9.8% |
| Q3 2022 | Nov 7, 2022 · After close | −2.2% |
| Q2 2022 | Aug 12, 2022 · Before open | +8.0% |
| Q1 2022 | May 13, 2022 · Before open | −1.0% |
| Q4 2021 | Mar 29, 2022 · Before open | +2.1% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · Before open | +1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 20 slides | March 2026 |
| IPO Roadshow (July 2021) | IPO roadshow | 12 slides | Jul 12, 2021 |
Financings
| Raise | Date |
|---|---|
| Debt financing Closed: US$3M raised Use of proceeds: Fund clinical and operating activities to complete the Phase 1 study of HCW9302 in alopecia areata and establish the Recommended Phase 2 Dose | Nov 5, 2026 |
| Private placement of units (pre-funded warrants with rights to common warrants) Announced: US$1.5M · US$1.6599 a unit · Warrants at US$1.66 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Continue HCW9302 clinical trials, advance IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes | Sep 24, 2026 |
| Private placement of units (common stock or pre-funded warrants, with common warrants) Announced: US$1.6M · US$2.585 a unit · Warrants at US$2.585 for 66 months Buyers: Hing C. Wong, Ph.D.; Scott Garrett; Lee Flowers Insiders: CEO Hing C. Wong, Chairman Scott Garrett and SVP Lee Flowers participated on the same terms Use of proceeds: Continue HCW9302 clinical trials, advance IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes | Jul 29, 2026 |
| Public offering of units (one share of common stock or pre-funded warrant and one warrant) Announced: about US$1.5M · US$0.6055 a unit · 1 warrant at US$0.6055 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Preclinical and clinical development, including HCW9302 clinical trials, and general corporate purposes | Feb 18, 2026 |
| Warrant exercise of common stock upon exercise of outstanding warrants Announced: about US$4M · US$2.66 a share · ½ warrant at US$2.41 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC | Nov 19, 2025 |
| Public offering of units (one share of common stock or pre-funded warrant and two warrants) Closed: US$5M raised · US$7.45 a unit · Warrants at US$7.45 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Open clinical sites for the Phase 1 trial of HCW9302 in an autoimmune disorder | May 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$8.00 a share on Jul 19, 2021.
- Price
- US$8.00 a share
- Shares offered
- 7,000,000 shares of common stock
- Offering size
- US$56 million
- Underwriters' option
- Up to 1,050,000 more shares
- Underwriters
- EF HUTTON, REVERE SECURITIES LLC · In the order on the cover
- Shares delivered
- On or about Jul 22, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 16, 2021 |
| Filed publicly | May 26, 2021 |
| Amended 3 times | Newest Jul 9, 2021 |
| Shares registered with an exchange | Jul 9, 2021 |
| Declared effective by the SEC | Jul 19, 2021 |
| Final prospectus, with the price | Jul 21, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 21, 2021 |
| EFFECT · Notice that a registration is effective | Jul 19, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 19, 2021 |
| CORRESP · Letter to the SEC | Jul 16, 2021 |
| CORRESP · Letter to the SEC | Jul 16, 2021 |
| CORRESP · Letter to the SEC | Jul 15, 2021 |
| CERT · Exchange's certificate of listing | Jul 15, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| FWP · Free writing prospectus | Jul 12, 2021 |
All 22 filings
| Filing | Filed |
|---|---|
| 8-A12B · Registration of shares for listing on an exchange | Jul 9, 2021 |
| S-1/A · Registration statement, amended | Jul 9, 2021 |
| FWP · Free writing prospectus | Jul 7, 2021 |
| S-1/A · Registration statement, amended | Jul 7, 2021 |
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| S-1/A · Registration statement, amended | Jun 15, 2021 |
| UPLOAD · Letter from the SEC | Jun 10, 2021 |
| CORRESP · Letter to the SEC | Jun 4, 2021 |
| CORRESP · Letter to the SEC | May 26, 2021 |
| S-1 · Registration statement | May 26, 2021 |
| UPLOAD · Letter from the SEC | May 13, 2021 |
| DRS · Draft registration statement | Apr 16, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 21, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 54.2K | 2.57M | 2.84M | 6.72M | 0 | 4.10M | 0 |
| Cost of revenue | 43.4K | 1.61M | 2.28M | 4.14M | 0 | 421.8K | |
| Gross profit | 10.8K | 959.4K | 560.4K | 2.59M | 0 | 4.10M | -421.8K |
| Research and development | 5.44M | 6.39M | 7.68M | 9.34M | 8.17M | 7.26M | 5.14M |
| Selling, general and administrative | 7.70M | 21.9M | 13.1M | 7.99M | 5.09M | 2.44M | 1.80M |
| Operating income | -13.2M | -29.5M | -25.7M | -15.1M | -13.4M | -5.82M | -7.37M |
| Depreciation and amortization | 1.04M | 1.18M | 1.14M | 717.9K | 543.6K | 572.9K | 421.8K |
| EBITDA | -12.1M | -28.3M | -24.6M | -14.4M | -12.8M | -5.25M | -6.94M |
| Interest expense | 845.1K | 654.3K | 283.0K | 126.7K | 0 | 0 | 0 |
| Income before tax | -7.96M | -30.0M | -25.0M | -14.9M | -12.9M | -5.80M | -7.29M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | -72.4K |
| Net income | -7.96M | -30.0M | -25.0M | -14.9M | -12.9M | -5.80M | -7.29M |
| Earnings per share, basic | -10.63 | -30.96 | -0.70 | -0.42 | -0.69 | -1.49 | -1.19 |
| Earnings per share, diluted | -10.63 | -30.96 | -0.70 | -0.42 | -0.69 | -1.49 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.95M | 4.67M | 3.60M | 22.3M | 11.7M | 8.46M | 7.36M |
| Short-term investments | 0 | 0 | 0 | 9.74M | 25.0M | 0 | |
| Receivables | 32.2K | 582.2K | 1.54M | 417.7K | 133.0K | 2.50M | |
| Inventory | 1.39M | 2.20M | 538.3K | ||||
| Current assets | 2.28M | 5.70M | 6.40M | 34.1M | 40.5M | 12.1M | 8.03M |
| Property, plant and equipment | 20.9M | 22.9M | 20.5M | 10.8M | 1.12M | 1.62M | 2.00M |
| Total assets | 24.5M | 30.2M | 28.5M | 46.8M | 53.5M | 15.4M | 10.1M |
| Accounts payable | 13.1M | 22.3M | 6.17M | 1.23M | 223.7K | 155.3K | 392.3K |
| Current liabilities | 21.1M | 29.6M | 8.75M | 2.96M | 2.32M | 1.00M | 1.07M |
| Long-term debt | 7.38M | 6.30M | 6.41M | ||||
| Total debt | 6.81M | 13.7M | 6.30M | 6.41M | 0 | 567.3K | |
| Total liabilities | 21.8M | 37.0M | 15.1M | 9.38M | 2.32M | 1.00M | 1.07M |
| Shareholders' equity | 2.76M | -6.77M | 13.5M | 37.4M | 51.2M | -16.7M | 9.00M |
| Shares outstanding | 3.14M | 3.14M | 6.73M | 44.9M | 37.8M | 35.9M | 6.12M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -13.4M | -14.2M | -22.5M | -10.4M | -11.0M | -10.4M | -6.77M |
| Capital spending | 0 | -261.6K | -6.20M | -10.3M | -47.3K | -186.7K | -1.46M |
| Free cash flow | -13.4M | -14.5M | -28.7M | -20.7M | -11.0M | -10.6M | -8.23M |
| Cash from investing | 0 | -261.6K | 3.80M | 14.7M | -35.0M | -186.7K | -1.46M |
| Cash from financing | 10.7M | 15.6M | -14.5K | 6.27M | 49.3M | 11.7M | 13.4M |
| Dividends paid | -2.82M | ||||||
| Share buybacks | -174.8K | ||||||
| Change in cash | -2.72M | 1.08M | -18.7M | 10.6M | 3.27M | 1.10M | 5.22M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Meeting outcome | SEC |
| PRE 14A · Preliminary proxy statement | Nov 18, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 8-K · Current report | Nov 5, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Oct 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 8, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 8, 2026 | Other filings | SEC |
| D | Oct 8, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-1 · Registration statement | Oct 2, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Oct 1, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 24, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| PRER14A | Sep 9, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Sep 4, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 28, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 28, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 26, 2026 | Other filings | SEC |
| S-1 · Registration statement | Aug 20, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 10-Q/A · Quarterly report, amended | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Current report | SEC |
| D | Aug 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 29, 2026 | Material contract | SEC |
| POS AM · Amendment to an effective registration | Jul 16, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jun 30, 2026 | Current report | SEC |
| 8-K · Current report | Jun 26, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 22, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 18, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 16, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| 8-K · Current report | Jun 15, 2026 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Jun 12, 2026 | Other filings | SEC |
| D | Jun 8, 2026 | Other filings | SEC |
| S-1 · Registration statement | Jun 8, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 21, 2026 | Material contract | SEC |
| POS AM · Amendment to an effective registration | May 18, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| POS AM · Amendment to an effective registration | May 13, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 29, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| S-1/A · Registration statement, amended | Apr 24, 2026 | Offer document | SEC |
| S-1 · Registration statement | Apr 23, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2026 | Current report | SEC |
| DRS · Draft registration statement | Apr 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Mar 17, 2026 | Material contract | SEC |
| DEF 14A · Proxy statement | Mar 13, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 3, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 8-K · Current report | Feb 19, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Feb 19, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| S-1/A · Registration statement, amended | Feb 17, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Feb 13, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 13, 2026 | Material contract | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2026 | Other filings | SEC |
| S-1 · Registration statement | Feb 11, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2026 | Other filings | SEC |
| S-1 · Registration statement | Jan 9, 2026 | Offer document | SEC |
| 8-K · Current report | Dec 31, 2025 | Current report | SEC |
| DRS · Draft registration statement | Dec 19, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 20, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 18, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 8-K · Current report | Oct 16, 2025 | Current report | SEC |
| DRS · Draft registration statement | Sep 30, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 5, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 19, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 18, 2025 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Aug 18, 2025 | Results | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2025 | Explanation request | SEC |
| 8-K · Current report | Aug 14, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Jul 18, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 8-K · Current report | Jun 4, 2025 | Material contract | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 8-K · Current report | May 15, 2025 | Material contract | SEC |
| 424B4 · Prospectus | May 15, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 13, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 9, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 9, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 1, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DRS · Draft registration statement | Apr 25, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 16, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 15, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 14, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2025 | Other filings | SEC |
| S-1 · Registration statement | Apr 7, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| 8-K · Current report | Apr 1, 2025 | Meeting outcome | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2025 | Results | SEC |
| 8-K · Current report | Mar 19, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| CT ORDER | Feb 26, 2025 | Other filings | SEC |
| DEFR14A | Feb 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Feb 21, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 21, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Feb 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 7, 2025 | Current report | SEC |
| 8-K · Current report | Feb 3, 2025 | Current report | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| D | Dec 5, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| 8-K · Current report | Nov 20, 2024 | Material contract | SEC |
| 424B2 · Prospectus | Nov 20, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 18, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Sep 20, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 23, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 8-K · Current report | Jul 18, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2024 | Meeting outcome | SEC |
| ARS/A · Annual report to shareholders, amended | May 20, 2024 | Annual report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | May 15, 2024 | Annual report | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| 8-K · Current report | May 1, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| D | Feb 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 22, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 23, 2023 | Insider trade | SEC |
This page holds 200 of 348 filings. Open Filings
Cap table
Built by 6ix from HCW Biologics Inc.’s releases · as of Nov 11, 2026
- Common shares
- 3,139,938
- Fully diluted
- 3,139,938
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 3,139,938 | Nov 11, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$7.45 · expire about May 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 3,139,938 |
| Jun 26, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lisa M. Giles Other companies: Milestone Pharmaceuticals Inc. (Director · Since at least Oct 1, 2020); GenMark Diagnostics Inc (Director · Feb 19, 2015 – Apr 22, 2021 · Past); Durata Therapeutics Inc (Director · Aug 3, 2012 – Nov 17, 2014 · Past) | Board Member · Since at least Oct 26, 2021 |
| Gary M. Winer Other companies: LENSAR, Inc. (Director · Since at least Sep 17, 2020) | Director · Oct 26, 2021 – May 16, 2025 · Past |
| Scott T. Garrett Other companies: Hologic Inc (Director · Dec 11, 2023 – Mar 14, 2024 · Past) | Director · Since at least Feb 20, 2024 |
| Hing C. Wong | Chief Executive Officer, Director · Since at least May 7, 2025 |
| Jack Egan | Vice President of Manufacturing and Development · Since at least Nov 4, 2026 |
| Jin-an Jiao | VP of Development · May 31, 2022 – May 31, 2022 · Past |
| Lee Flowers | Senior Vice President Business Development · Since at least Jul 19, 2021 |
| Nicole Valdivieso | Vice President Legal Affairs · Since at least Nov 4, 2026 |
| Peter Rhode | Chief Scientific Officer and Vice President Clinical Operations · Since at least Nov 17, 2023 |
| Rebecca Byam | Chief Financial Officer · Since at least Jul 19, 2021 |
All 12 people
| Person | Seat |
|---|---|
| Rick S Greene | Director · Jun 2, 2022 – May 7, 2025 · Past |
| Rick S. Greene | Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about HCW Biologics Inc.